[1]Kang SJ, Mintz GS, Park DW, et al. Mechanisms of In-Stent Restenosis After Drug-Eluting Stent Implantation Intravascular Ultrasound Analysis[J]. Circ Cardiovasc Interv, 2011, 4(1): 9-14.
[2]Ross R. Atherosclerosis an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
[3]江涛. P-选择素和内皮素1在下肢动脉硬化闭塞症患者介入治疗术后的表达[D]. 安徽：安徽医科大学，2012.
[4]冯晓东，蔡英年. 内皮素-1对血管平滑肌细胞增殖作用的研究进展[J]. 中国应用生理学杂志，1994，10（2）：189-191.
[5]任为，张彦，时德. 血浆内皮素与慢性下肢动脉缺血的相关性研究[J]. 重庆医科大学学报，2002，27（4）：439-440.
[6]史作磊，王坤，于剑，等. 血浆内皮素-1及NO对膝下动脉硬化闭塞症球囊扩张成形术后血管再狭窄的预测价值[J]. 中国现代普通外科进展，2015，2（18）：127-129.
[7]Fiessinger JN, Schafer M. Trial of iloprost versus aspirin treatmentfor critical limb ischaemia of thromboangiitisobliterans: the TAO Study[J]. Lancet, 1990, 335(8689): 555-557.
[8]Dormandy J. Use of the prostacyclin analogue iloprost in the treatment of patients with critical limb ischaemia[J]. Therapie, 1991, 46(4): 319-322.
[9]Lessiani G, Vazzana N, Cuccurullo C, et al. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost[J]. Thromb Haemost, 2011, 105(2): 321-328.
[10]Miyashita Y, Saito S, Miyamoto A, et al. Cilostazol increases skin perfusion pressure in severely ischemic limbs[J]. Angiology, 2011, 62(1): 15-17.
[11]Shalhoub J, Davies AH, Franklin IJ. Cilostazol may improve outcome in critical limb ischemia[J]. Int Angiol, 2009, 28(5): 363-366.
[12]Sigvant B, Wiberg-Hedman K, Bergqvist D, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences[J]. J Vasc Surg, 2007, 45(6): 1185-1191.
[13]Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease[J]. Am J Cardiol, 2001, 88(2): 112-117.
[14]何文军，黄家平，梁伟东，等. 氧化低密度脂蛋白和C-反应蛋白与冠状动脉支架置入术后再狭窄的关系研究[J]. 检验医学，2015，30（5）：484-488.
[15]Hojo Y, Ikeda U, Katsuki T, et al. Interleukin 6 expression incoronary circulation after coronary angioplasty as a risk factor for restenosis[J]. Heart, 2000, 84(1): 83-88.
[16]Dibra A, Mehilli J, Braun S, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting[J]. Am J Med, 2003, 114(9): 715-722.
[17]Tzoulaki I, Murray GD, Lee AJ, et al. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study[J]. Eur Heart J, 2007, 28(3): 354-362.
[18]Zurakowski A, Wojakowski W, Dzielski T, et al. Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting[J]. Kardiol Pol, 2009, 67(6): 623-630.
[19]Funayama H, Ishikawa SE, Kubo N, et al. Close association of regional interleukin-6 levels in the infarct-related culprit coronary artery with restenosis in acute myocardial infarction[J]. Circulation, 2006, 70(4): 426-429．
[20]吕磊，张柏根. 白细胞介素12促血管平滑肌细胞增殖的实验研究[J]. 中国现代医学杂志，2008，15（18）：2138-2141.
[21]Anguera I, Miranda-Guardiola F, Bosch X, et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina[J]. Am Heart J, 2002, 144(5): 811-817.
[22]Smith DA, Irving SD, Sheldon J, et al. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina[J]. Circulation, 2001, 104(7): 746-749.
[23]Feldman LJ, Aguirre L, Ziol M, et al. Interleukin 10 inhibits intimal hyperplasia after angioplasty or stent implantation in Hypercholesterolemic rabbits[J]. Circulation, 2000, 101(8): 908-916.
[24]Kaikita K, Ogawa H, Yasue H, et al. Soluble P-selectin is released into the coronary circulation after coronary spasm[J]. Circulation, 1995, 92(7): 1726-1730．
[25]苏子德，代怀静，王涛，等. 血浆P-选择素和内皮素-1预测冠状动脉内支架术后早期再狭窄的价值[J]. 中国介入心脏病学杂志，2006，14（4）：222-225.
[26]Shinkai S, Chaves PH, Fujiwara Y, et al. Beta 2-microglobulin for risk stratification of total mortality in the elderly population：comparison with cystatin C and C-reactive protein[J]． Arch intern Med, 2008, 168(2): 200-206．
[27]Touefsen DM. Vascular dermatan sulfate and heparin cofactor Ⅱ[J]. Prog Mol Biol Transl Sci, 2010, 93: 351-372．
[28]秦永林，滕皋军，郭金和，等. 下肢动脉球囊扩张成形术后血清β2微球蛋白变化及其对再狭窄或闭塞的预测作用[J]. 中华医学杂志，2012，21（92）：1453-1457.
[29]卢衡，郭平凡. 血清肝素辅助因子Ⅱ活性与下肢动脉硬化闭塞症介入术后再狭窄相关[J]. 中南大学学报：医学版，2015，40（2）：177-181.
[30]Benaron DA, Bowen FW. Varition of intial serum bilirubin rise in newborn infants with type of illness[J]. Lancet, 1991, 338(8759): 78．
[31]丁乐顺，刘占成. 血清胆红素检测与动脉粥样硬化的关系[J]. 江西医学检验，2005，23（3）：272-273.
[32]刘昆，辛世杰，张健，等. 贫血与下肢动脉硬化闭塞症相关性研究[J]. 中国血管外科杂志：电子版，2012，4（3）：161-162.
[33]Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction[J]. J Am Coll Cardiol, 2001, 38(4): 955-962.
[34]Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure[J]. Circulation, 2003, 107(2): 223-225.
[35]Wang XY, Qiu MH, Li J, et al. Impacts of anemia on 3-year ischemic events in patients undergoing percutaneous coronary intervention: a propensity matched study[J]. J Thorac Dis, 2015, 7(11): 1951-1959.
[36]王海君，刘冰，王海洋，等． 胆红素、尿酸水平与下肢动脉硬化闭塞症相关性研究[J]． 中国血管外科杂志：电子版，2010，2（1）：45－49．
[37]Desormais I, Aboyans V, Bura A, et al. Anemia, an independent predictive factor for amputation and mortality in patients hospitalized for peripheral artery disease[J]. Eur J Vasc Endovasc Surg, 2014, 48(2): 202-207.
[38]Toso A, Leoncini M, Maioli M, et al. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction[J]. J Cardiovasc Med, 2011, 12(5): 318-321．